RioDerm-004 by Rion for Fistula: Likelihood of Approval

RioDerm-004 is under clinical development by Rion and currently in Phase I for Fistula.

Ipsen, Skyhawk ink deal worth up to $1.8B; Hepion to wind down NASH trial

Plus, news about Aslan, Takeda, Astellas, Sumitomo Mitsui, Kynos Therapeutics, Oculis and Vaxxinity: Ipsen, Skyhawk Therapeutics pen neurological deal: Ipsen and Skyhawk plan to develop

April 23, 2024

What’s next in the Kaiser Permanente strike

You’re reading the web edition of Health Care Inc., STAT’s weekly newsletter following the flow of money through the health care system. Sign up here to get

October 10, 2023

NIH will bring clinical research into primary care offices with $30 million pilot

For many Americans, health care means going to a local primary care office. But the vast majority of clinical research is conducted inside the walls

June 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.